Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in HER2- Inflammatory Breast Cancer
NCT00820547Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jan 2009
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in inflammatory breast cancer (IBC), sponsored by Unicancer. Started Jan 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT00820547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00820547.